AstraZeneca Fourth Quarter and Full-Year 2011 Results - Interviews

LONDON, February 2, 2012 /PRNewswire/ --

AstraZeneca, the Anglo-Swedish pharmaceutical company, said that government price intervention had reduced its revenues by about $1bn as it announced further restructuring alongside its full-year results.

In an interview on http://www.cantos.com, David Brennan, CEO, discusses AstraZeneca's portfolio performance including Brilinta and Crestor, and the prospects for the  pipeline in light of recent disappointments.

He also reaffirms his strong commitment to returning cash to shareholders. 

Also interviewed about the rationale behind the latest phase of the restructuring, Martin Mackay, President, R&D, said:

"We have to be a very flexible organisation to make sure that we're dynamic enough to work in the environment that we work in but also produce great medicines."

Tony Zook, EVP, Global Commercial, also talks about his confidence in AstraZeneca's ability to deliver top line performance and the importance of emerging markets for future growth. 

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.


SOURCE AstraZeneca

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.